SCHEMBL95542

SCHEMBL95542

CC(C)(C)c1ccc(-c2noc(CC[O])n2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.69
TP53 P04637 7/20 0.69
RAB9A P51151 6/20 0.69
KLF5 Q13887 3/20 0.69
NPC1 O15118 6/20 0.67
CYP1A2 P05177 2/20 0.67
CYP2C19 P33261 2/20 0.67
CYP2C9 P11712 1/20 0.67
TSHR P16473 2/20 0.66
ALDH1A1 P00352 1/20 0.66
LMNA P02545 3/20 0.63
HPGD P15428 3/20 0.63
MAPT P10636 7/20 0.58
MITF O75030 2/20 0.54
TNF P01375 1/20 0.54
NOD2 Q9HC29 1/20 0.54
NOD1 Q9Y239 1/20 0.54
KDM4E B2RXH2 1/20 0.53
GAA P10253 1/20 0.53
HTT P42858 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL95161 0.88 TP53 (0.64) SMN1; SMN2TP53RAB9AKLF5NPC1
SCHEMBL95543 0.85 SMN1; SMN2 (0.69) SMN1; SMN2TP53RAB9AKLF5NPC1
SCHEMBL157198 0.83 RAB9A (0.62) SMN1; SMN2TP53RAB9AKLF5NPC1
SCHEMBL2245578 0.81 TP53 (0.60) SMN1; SMN2TP53RAB9AKLF5NPC1
SCHEMBL95162 0.81 RAB9A (0.64) SMN1; SMN2TP53RAB9AKLF5NPC1
SCHEMBL417374 0.74 NPC1 (0.61) SMN1; SMN2TP53RAB9AKLF5NPC1
SCHEMBL876239 0.73 S1PR1 (0.78)
SCHEMBL4227167 0.72 RAB9A (0.53) SMN1; SMN2TP53RAB9AKLF5NPC1
SCHEMBL8830004 0.72 NPC1 (0.59) SMN1; SMN2TP53RAB9AKLF5NPC1
SCHEMBL2088387 0.72 S1PR1 (0.65) LMNAMAPTSIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB SMN1; SMN2 3998/4885TP53 3154/4885RAB9A 3886/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 SMN1; SMN2 3084/4885TP53 1280/4885RAB9A 2273/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 SMN1; SMN2 3084/4885TP53 1280/4885RAB9A 2273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.